GeneVector Therapeutics has full intellectual property of and industry leading expertise in genetically engineering and production of AAV, and is focused on developing novel AAV based gene therapies for treating AMD, XLRS, etc. GeneVector Therapeutics is based in Chengdu, China.
Investors 1
| Date | Name | Website |
| - | Ming Capit... | mingcapita... |
Mentions in press and media 1
| Date | Title | Description |
| 06.02.2024 | Deals in brief: CarbonHQ and Oobit secure funding, Nio Capital completes second RMB fund, 15 other China and India deals, and more | Investible and Galileo Ventures lead CarbonHQ’s pre-seed round CarbonHQ, an early-stage carbon project management platform, has secured AUD 600,000 (USD 390,760) in a pre-seed funding round jointly led by Investible’s Climate Tech Fund and ... |